Latino Semaglutide Study

Loma Linda University119 enrolled

Overview

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

119

Conditions

Obesity Obesity; Drug Overweight or Obesity Weight Loss Weight Loss Trajectory Weight, Body

Interventions

Semaglutide 2.4mgDRUG

The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.

PlaceboDRUG

A placebo will be given to the control group per the schedule outlined in the armed description.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Self-identify as being of Hispanic/Latino ethnicity * BMI \>30 * Age 18-75 years old * Able to provide informed consent before any trial related activities Exclusion Criteria: * Current cancer treatment * Diabetes, Type 1 or Type 2 * Eating disorders * Medication use targeting the GPL-1 system * In the last 30 days, attempted to lose weight by lifestyle modification alone or with the use of anti-obesity medications resulting in more than 5 pounds of weight loss. * History of bariatric surgery * Use of obesogenic medications (including but not limited to steroids, haloperidol, clozapine, risperidone, olanzapine, amitriptyline, imipramine, paroxetine, and lithium) which cannot be substituted or stopped. * Pregnant or planning to become pregnant in the next 8 months * Genetic disorders and/or physical or mental handicaps that would limit participation in the study and/or the intensive lifestyle intervention. * Any contraindication to semaglutide 2.4 mg including personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia Syndrome Type 2, hypersensitivity to semaglutide 2.4 mg or any product components. * Any known or suspected allergy to semaglutide 2.4 mg or related products * Previous participation in this trial, either initial screening or group randomization

Locations (1)

Loma Linda University Health

Loma Linda, California, United States

Outcomes

Primary Outcomes

Assessment of weight loss.

Assessment will be based on pounds lost between baseline and final study visit.

Time frame: Change between baseline and final study visit, seven months post baseline.

Secondary Outcomes

Food Addiction Assessment

Yale Food Addiction Scale Survey administered to subjects at baseline and month four of treatment. Assessment results based on multiple survey questions regarding intake of specific food types (sugar, starch, sweet, salty, savory).

Time frame: Change between baseline and month four of treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.